MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: Association with wild-type p53 accumulation

Modern Pathology

Volumn 10, Issue 8, 1997, Pages 785-792

  Pruneri, Giancarlo ^a   Pignataro, Lorenzo ^a   Carboni, Nadia ^a   Luminari, Stefano ^a   Capaccio, Pasquale ^a   Neri, Antonino ^a   Buffa, Roberto ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Immunohistochemistry; Laryngeal cancer; MDM 2; P53

Indexed keywords

ONCOPROTEIN; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN TISSUE; LARYNX CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, SOUTHERN; CARCINOMA, SQUAMOUS CELL; DNA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030805232     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Cordon-Cardo C. Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-60.
2. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
3. Kernohan NM, Cox LS. Regulation of apoptosis by bcl-2 and its related proteins: immunochemical challenges and therapeutic implications. J Pathol 1996;179:1-3.
4. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
5. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler W, Vogelstein B. Oncoprotein MDM-2 conceals the activation domain of tumour suppressor p53. Nature 1993;362:857-60.
6. Keleti J, Quezado MM, Abaza MM, Reffeld M, Tsokos M. The MDM-2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol 1996;149:143-51.
7. Meltzer PS. MDM-2 and p53: a question of balance. J Natl Cancer Inst 1994;86:1265-6.
8. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10:1565-9.
9. Oliner JD, Kinler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
10. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, et al. p53 mutation and MDM-2 amplification in human soft tissue sarcomas. Cancer Res 1993;53:2231-4.
11. Marchetti A, Buttitta F, Pellegrini S, Merlo G, Chella A, Angeletti CA, et al. MDM-2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in absence of p53 gene mutation. Diagn Mol Pathol 1995;4:93-7.
12. McCann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G, et al. Amplification of the MDM-2 gene in human breast cancer and its association with MDM-2 and p53 protein status. Br J Cancer 1995;71:981-5.
13. Riou G, Barrois M, Prost S, Terrier MJ, Theodore C, Levine AJ. The p53 and MDM-2 genes in human testicular germ-cell tumors. Mol Carcinogen 1995;12:124-31.
14. Esteve A, Lehman T, Jiang W, Weinstein B, Harris CC, Ruol A, et al. Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of MDM-2 amplification in human esophageal carcinomas. Mol Carcinogen 1993;8:306-11.
15. Waber PG, Chen J, Nisen P. Infrequency of MDM-2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res 1993;53:6028-30.
16. Foulkes WD, Stamp GWH, Afzal S, Lalani N, McFarlane CP, Trowsdale J, et al. MDM-2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer 1995;72:883-8.
17. Öfner D, Maier H, Riedmann B, Holzberger P, Nogler M, Tötsch M, et al. Immunohistochemically detectable p53 and MDM-2 oncoprotein expression in colorectal carcinoma: prognostic significance. J Clin Pathol Mol Pathol 1995;48: 12-6.
18. Gelsleichter L, Gown AM, Zarbo RJ, Wang E, Coltrera MD. p53 and MDM-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, MDM-2, and markers of cell proliferation in primary versus metastatic tumors. Mod Pathol 1995;8:530-5.
19. Segers K, Backhovens H, Singh SK, De Voecht J, Ramael M, Van Broeckhoven C, et al. Immunoreactivity for p53 and MDM-2 and the detection of p53 mutations in human malignant mesothelioma. Virchows Arch 1995;427-31.
20. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, et al. Molecular abnormalities of MDM-2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54: 794-9.
21. Zhou M, Yeager AM, Smith SD, Findley HW. Overexpression of the MDM-2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 1995; 85:1608-14.
22. Qian W, Hu LF, Chen F, Wang Y, Magnusson KP, Kashuba E, et al. Infrequent MDM-2 gene amplification and absence of gross WAF-1 gene alterations in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol 1995;31:328-32.
23. Girod SC, Cesarz D, Fischer U, Krueger GRF. Detection of p53 and MDM-2 protein expression in head and neck carcinogenesis. Anticancer Res 1995;15:1453-8.
24. Matsumura T, Yoshihama Y, Kimura T, Shintani S, Alcalde RE. p53 and MDM-2 expression in oral squamous cell carcinoma. Oncology 1996;53:308-12.
25. Pruneri G, Pignataro L, Fracchiolla NS, Ferrero S, Capaccio P, Carboni N, et al. p53 protein expression in laryngeal squamous cell carcinomas bearing wild-type and mutated p53 gene. Histopathology 1996;28:513-8.
26. Shanmugaratnam K, Sobin IN, et al. Histological typing of tumours of the upper respiratory tract and ear. 2nd ed. Berlin: Springer Verlag; 1991.
27. Ravetch JV, Siebenlist V, Korsmeyer SJ, Waldman TA, Leder P. Structure of the immunoglobulin locus: characterization of embryonic and rearranged J and D regions. Cell 1981;27: 383-91.
28. Leng P, Brown DR, Shivakumar CV, Deb S, Deb SP. N-terminal 130 amino acids of MDM-2 are sufficient to inhibit p53-mediated transcriptional activity. Oncogene 1995;10:1275-82.
29. Marchetti A, Buttitta F, Girlando S, Dalla Palma P, Pellegrini S, Fina P, et al. MDM-2 gene alterations and MDM-2 protein expression in breast carcinomas. J Pathol 1995;175:31-8.
30. Gorgoulis VG, Zoumpourlis V, Rassidakis GZ, Karameris GZ, Rassidakis AN, Spandidos DA, et al. A molecular and immunohistochemical study of the MDM-2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol 1996; 180:129-37.
31. Lianes P, Orlow I, Zhang Z-F, Oliva MR, Sarkis AS, Reuter VE, et al. Altered patterns of MDM-2 expression in human bladder cancer. J Natl Cancer Inst 1994;86:1325-30.
32. Zhu D, Wang L, Zhang C, Wang X, Mao X, Jia Y, et al. No evidence for the amplifications of MDM-2 and c-myc genes involved in the genetic susceptibility to esophageal cancer in a high-risk area of North China. Cancer Genet Cytogenet 1996;89:184-5.
33. Landers JE, Haines DS, Strauss JF III, George DL. Enhanced translation: a novel mechanism of MDM-2 oncogene overexpression identified in human tumor cells. Oncogene 1994; 9:2745-50.
34. Wietege T, Voss B, Müller KM. Detection of MDM-2 protooncogene in paraffin-embedded bronchial epithelium. J Cancer Res Clin Oncol 1994;120:252-5.
35. Capaccio P, Carboni N, Pignataro L, Scotti A, Ottaviani F, Pruneri G. Cyclin D1, p53, MDM-2, and Ki-67 protein expression in preneoplastic lesions of the larynx. J Chemotherapy 1997;9:7-8.
36. Barak Y, Juven T, Haffner R, Oren M. MDM-2 expression is induced by wild-type p53 activity. EMBO J 1993;12:461-8.